Halozyme Therapeutics Inc (HALO)

[XenaLives]

Torley quote from recent conference call:

In summary, I'm very encouraged by the development over the quarter in our PEGPH20 clinical program and by the advances across our ENHANZE portfolio. As we continue to enroll patients in our HALO-301 global Phase III trial, support from opinion leaders and investigators remain high, and we look forward to expanding upon the top line results from the HALO-202 Phase II study during the upcoming oral presentation at ASCO.

We also look forward to the possibility of sharing initial response rate data from patients from the KEYTRUDA combination study by the end of the year, as we further explore the pan-tumor potential of PEGPH20. Our ENHANZE portfolio continues to drive value for the company as currently marketed products advance into new geographies and products progress into and through the clinic. In 2017, key events include the potential approval of rituximab SC in the United States and advances in the subcutaneous development program for DARZALEX and Perjeta. These programs serve to create our next inflection points in ENHANZE growth. Above all, we remain confident with the investments we're making in both pillars of our strategy and that they will generate near and long-term value for our shareholders and partners.

https://finance.yahoo.com/news/edited-transcript-halo-earnings-conference-124628498.html